Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 12/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15722708 | 0.87 | PIK3C3 (0.47) | PIK3C3AURKAAURKBRETIGF1R | |
| SCHEMBL63682 | 0.83 | AURKA (0.46) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL15704951 | 0.82 | AURKA (0.41) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL15667867 | 0.82 | AURKA (0.41) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL220647 | 0.81 | PAK4 (0.57) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL15667945 | 0.81 | PIK3C3 (0.52) | PIK3C3IGF1R | |
| SCHEMBL12105461 | 0.79 | AURKA (0.52) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL4116079 | 0.78 | PAK4 (0.48) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL18166015 | 0.78 | MEN1 (0.43) | GSK3BPIK3C3AURKAAURKBPAK4 | |
| SCHEMBL12102876 | 0.77 | MEN1 (0.52) | GSK3BPIK3C3AURKAAURKBPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10160749-B2 | Substituted indol-5-ol derivatives and their therapeutical applications | NANTBIO, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9458137-B2 | Substituted indol-5-ol derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
| EP-2968332-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NantBioScience, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2914265-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Nant Holdings IP, LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014071378-A9 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014145403-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014071378-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | GSK3B 95/4885PIK3C3 507/4885AURKA 796/4885 |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | GSK3B 127/4885PIK3C3 471/4885AURKA 1063/4885 |
| US-10160749-B2 | Substituted indol-5-ol derivatives and their therapeutical applications | GRK5, GRK3, MTMR1 | GSK3B 127/4885PIK3C3 471/4885AURKA 1063/4885 |
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | GRK5, GRK3, CDK5 | GSK3B 95/4885PIK3C3 507/4885AURKA 796/4885 |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | GSK3B 127/4885PIK3C3 471/4885AURKA 1063/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | GSK3B 95/4885PIK3C3 507/4885AURKA 796/4885 |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | GSK3B 314/4885PIK3C3 898/4885AURKA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.